Drugs / Voncento
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Voncento | — | 2013-08-12 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02552576 | Oct 2015 → Feb 2018 | von Willebrand disease (hereditary or acquired) | CSL Behring | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Voncento | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02552576 ↗ |
| Modality | Protein / enzyme biologic | “Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate” NCT02552576 ↗ |